本文關(guān)鍵詞：加味不換金正氣散治療腹瀉型腸易激綜合征寒濕蘊結(jié)證的療效評價研究　出處：《南京中醫(yī)藥大學》2016年碩士論文　論文類型：學位論文

  更多相關(guān)文章： 腹瀉型腸易激綜合征 加味不換金正氣散 培菲康 寒濕蘊結(jié)證

【摘要】：目的：從理論研究及臨床研究兩方面探討加味不換金正氣散治療腹瀉型腸易激綜合征(irritable bowel syndrome-Diarrhea,簡稱IBS-D)寒濕蘊結(jié)證的臨床療效,并探討其治療機制。方法：將符合納入標準的60例患者采用隨機對照法,分為治療組和對照組各30例。治療組患者服用加味不換金正氣散,對照組患者服用雙歧桿菌三聯(lián)活菌膠囊(培菲康)治療,療程為4周,記錄治療前、2周后及4周后的癥狀評分。結(jié)果：治療組能顯著改善患者的臨床癥狀,尤其在總癥狀積分以及受涼勞累后發(fā)作或加重、畏寒怕冷、食欲不振、腸鳴癥狀方面,其療效優(yōu)于對照組(P0.05或P0.01)。在改善腹痛或腹部不適、大便次數(shù)、大便性狀方面兩組療效相當(P0.05)。中醫(yī)證候療效方面,治療組和對照組臨床治愈例數(shù)分別為3例和1例,顯效例數(shù)分別是22例和11例,有效例數(shù)分別是4例和15例,無效例數(shù)分別是1例和3例。治療組的愈顯率和有效率分別是83.3%和96.7%,對照組愈顯率和有效率分別為40%和90%。經(jīng)等級資料非參數(shù)檢驗,P0.05,差異有統(tǒng)計學意義,說明治療組中醫(yī)證候療效方面優(yōu)于對照組。兩組在治療期間均未發(fā)現(xiàn)明顯不良反應。結(jié)論：加味不換金正氣散及培菲康均對IBS-D寒濕蘊結(jié)證有明顯療效,且中藥加味不換金正氣散的療效優(yōu)于口服培菲康,值得臨床推廣應用。
[Abstract]:Objective: to explore the treatment of diarrhea irritable bowel syndrome (IBS) with modified Buxiangjin Zhengqi Powder from two aspects of theoretical and clinical study. Irritable bowel syndrome-Diarrhea. The clinical effect of IBS-D on the syndrome of cold and dampness accumulation and its therapeutic mechanism were discussed. Methods: 60 patients who met the inclusion criteria were treated with randomized controlled method. Treatment group and control group 30 cases each. The treatment group patients were treated with modified not changing Jin Zhengqi powder, the control group patients were treated with Bifidobacterium triple viable capsule (Peifeikang), the course of treatment was 4 weeks, recorded before the treatment. Results: the clinical symptoms of the patients were significantly improved in the treatment group, especially in the total symptom score, attack or aggravation after cold and tiredness, fear of cold, loss of appetite and bowel pain. The curative effect is better than that of control group (P0.05 or P0.01). In improving abdominal pain or abdominal discomfort, defecation frequency, defecation character, the two groups have the same curative effect as P0.05. Chinese medicine syndromes curative effect. The clinical cases of treatment group and control group were 3 cases and 1 case, 22 cases and 11 cases of marked effect, 4 cases of effective cases and 15 cases of effective cases, respectively. The effective rate and effective rate of the treatment group were 83.3% and 96.7% respectively. The effect rate and effective rate of control group were 40% and 90, respectively. The difference was statistically significant by non-parametric test of grade data (P0.05). The treatment group is superior to the control group in the curative effect of TCM syndromes. No obvious adverse reactions were found in the two groups during the treatment. Conclusion: Jiawei not changing Jin Zhengqi Powder and Peifeikang have obvious curative effect on IBS-D cold and dampness accumulation syndrome. The curative effect of modified Chinese medicine without changing Jin Zhengqi powder is better than that of oral peeficam, so it is worth popularizing in clinic.
【學位授予單位】：南京中醫(yī)藥大學
【學位級別】：碩士
【學位授予年份】：2016
【分類號】：R259

【參考文獻】

相關(guān)期刊論文 前1條

1 Piero Portincasa;Antonio Moschetta;Giuseppe Baldassarre;Donato F. Altomare;Giuseppe Palasciano;;Pan-enteric dysmotility,impaired quality of life and alexithymia in a large group of patients meeting ROMEⅡ criteria for irritable bowel syndrome[J];World Journal of Gastroenterology;2003年10期

，

本文編號：1364462